Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
Medpage Today on MSN4d
FDA Expands Approval of Ribociclib to Early Breast Cancer
The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Targeted Oncology4d
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...
oncnursingnews5d
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
SurvivorNet on MSN4d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
Pharmabiz3d
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.